Precision BioSciences to Report Q4 and Fiscal Year 2025 Results

Gene editing company to provide business update on March 12, 2026

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Precision BioSciences, Inc., a clinical-stage gene editing company utilizing its proprietary ARCUS® platform, announced that it will publish financial results for the fourth quarter of 2025 and provide a business update on March 12, 2026.

Why it matters

As a clinical-stage gene editing company, Precision BioSciences' financial and operational updates are closely watched by investors and the broader biotech industry. The ARCUS® platform is a novel approach to gene editing that differs from other technologies, and the company's pipeline of in vivo gene editing candidates targeting genetic and infectious diseases is of significant interest.

The details

Precision BioSciences is a clinical-stage gene editing company that uses its proprietary ARCUS® platform to develop in vivo gene editing therapies. The ARCUS® platform is designed to deliver more defined therapeutic outcomes through its unique cutting mechanism, smaller size, and simpler structure compared to other gene editing technologies.

  • Precision BioSciences will publish Q4 2025 financial results and provide a business update on March 12, 2026.

The players

Precision BioSciences, Inc.

A clinical-stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases.

Got photos? Submit your photos here. ›

The takeaway

Precision BioSciences' upcoming financial and operational update will provide insights into the progress of its gene editing pipeline and the continued development of its differentiated ARCUS® platform, which aims to deliver lasting cures for genetic and infectious diseases.